Clinical Trials Directory

Trials / Completed

CompletedNCT00023101

Lead, Endocrine Disruption and Reproductive Outcomes

Status
Completed
Phase
Study type
Observational
Enrollment
800 (planned)
Sponsor
National Institute of Environmental Health Sciences (NIEHS) · NIH
Sex
All
Age
20 Years – 34 Years
Healthy volunteers
Accepted

Summary

This prospective cohort study of 400 lead exposed and 400 non-lead exposed women and their husbands assesses endocrine dysfunction and adverse reproductive outcomes. Residing in two study areas in Shenyang, China, the women are married, 20 and 34 years of age, never smokers, have obtained permission to have a child, and have attempted to become pregnant over the course of the study. Lead exposure is defined by lead levels in blood samples collected at the baseline survey (both women and their husbands), first and second trimesters, and at delivery (both maternal and cord blood). Endocrine dysfunction is monitored by urinary hormone metabolites including follicle-stimulating hormone (FSH), luteinizing hormone (LH), estrone conjugates (E1C), and pregnanediol-3-glucuronide (PdG). Reproductive endpoints include menstrual disturbance, time to conception, spontaneous abortion, preterm delivery, and low birth weight.

Conditions

Timeline

Start date
1996-08-01
First posted
2001-08-24
Last updated
2006-03-23

Source: ClinicalTrials.gov record NCT00023101. Inclusion in this directory is not an endorsement.

Lead, Endocrine Disruption and Reproductive Outcomes (NCT00023101) · Clinical Trials Directory